GlassScriptPhysician profile
Crystal Ray Broussard
NPI 1588688576
$2,356.85
in general payments reported to CMS, 2019-2025
34 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $89.93 · 2021: $81.62 · 2022: $374 · 2023: $286 · 2024: $713 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285.27 | 2020-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $276.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.20 | 2022-2024 | Trulance |
| Janssen Pharmaceuticals, INC | $230.37 | 2024-2025 | Spravato |
| Abbvie INC. | $180.84 | 2022-2025 | Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $100.54 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $98.73 | 2020-2025 | Eohilia, Trintellix |
| Astrazeneca Pharmaceuticals LP | $73.05 | 2019-2024 | Breztri, Airsupra |
| Revance Therapeutics, INC. | $71.88 | 2024-2025 | Daxxify |
| Abbott Laboratories | $66.70 | 2022-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $57.52 | 2025 | Inspire |
| Amgen INC. | $53.71 | 2020-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $51.62 | 2022-2023 | |
| Mannkind Corporation | $43.30 | 2019 | |
| Glaxosmithkline, LLC. | $42.93 | 2023-2025 | Shingrix, Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $40.27 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $36.69 | 2025 | Korlym |
| Ardelyx, INC. | $36.09 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $35.40 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $33.40 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.26 | 2019-2025 | Jardiance |
| Genentech USA, INC. | $28.43 | 2019-2020 | |
| Bausch Health US, LLC | $26.04 | 2019 | |
| Mauna Kea Technologies, INC. | $25.29 | 2021 | |
| Astellas Pharma US INC | $24.89 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $24.39 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.77 | 2019-2020 | |
| Braeburn INC. | $22.19 | 2024 | Brixadi |
| Alkermes, INC. | $18.70 | 2025 | Aristada, Lybalvi |
| Currax Pharmaceuticals LLC | $17.59 | 2023 | Contrave, Onzetra Xsail |
| Acella Pharmaceuticals, LLC | $16.93 | 2023 | NP Thyroid 60 |
| Exact Sciences Corporation | $15.52 | 2023 | Cologuard Collection Kit |
| Neos Therapeutics, LP | $15.34 | 2019 | |
| Merz North America, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.